A5006648427- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Cancer Research and Treatments
- CAR-T cell therapy research
- Radiation Therapy and Dosimetry
- Cancer Immunotherapy and Biomarkers
- Digital Radiography and Breast Imaging
- AI in cancer detection
- Medical Imaging Techniques and Applications
- Cancer Diagnosis and Treatment
University of Leicester
2023-2025
University of Nottingham
2025
National Institute for Health Research
2024
Cancer Research UK
2024
Occupational Cancer Research Centre
2023
University of Kansas Medical Center
1992
Abstract Malignant mesothelioma is a rare tumour caused by asbestos exposure that originates mainly from the pleural lining or peritoneum. Treatment options are limited, and prognosis dismal. Although immune checkpoint blockade (ICB) can improve survival outcomes, determinants of responsiveness remain elusive. Here, we report outcomes multi-centre phase II clinical trial (MiST4, NCT03654833) evaluating atezolizumab bevacizumab (AtzBev) in patients with relapsed mesothelioma. We also use...
Abstract Background: Mesothelioma is a lethal cancer caused by asbestos. Effective therapy in the relapsed setting, following standard of care treatments lacking [1]. Inhibition Poly-ADP ribose polymerase (PARPi) mediates synthetic lethality cancers harboring DNA damage response gene (DDR) inactivation, notably BRCA1/2 resulting homologous recombination deficiency (HRD), and transcription replication conflicts (TRCs). In mesothelioma PARPi was clinically active MIST1 phase II trial [2],...
Background Malignant mesothelioma is a rapidly lethal cancer that has been increasing at an epidemic rate over the last three decades. Targeted therapies for have lacking. A previous study called MiST1 ( NCT03654833 ), evaluated efficacy of Poly (ADP-ribose) polymerase (PARP) inhibition in mesothelioma. This met its primary endpoint with 15% patients having durable responses exceeding 1 year. Therefore, there need to evaluate PARP inhibitors relapsed patients, where options are limited....